Biocryst Pharmaceuticals Inc (BCRX) Directors and Executive Officers

Officers & Directors

Executives:

1. Jon P. Stonehouse
- Position: President, Chief Executive Officer, and Director
- Mr. Stonehouse joined BioCryst Pharmaceuticals as CEO in 2015. He has extensive industry experience in the biotech and healthcare market, having held various positions such as CEO and board member at TESARO and CEO of AVEO Oncology.

2. Anthony J. Doyle
- Position: Chief Financial Officer
- Mr. Doyle joined BioCryst Pharmaceuticals as CFO in 2018. He has over 20 years of financial and accounting experience, with previous leadership roles at multiple biotech and pharmaceutical companies, including ArQule and Pharmion Corporation.

Directors:

1. George B. Abercrombie
- Position: Director

2. Machelle Sanders
- Position: Director

3. Alan G. Levin
- Position: Director

4. Jon P. Stonehouse
- Position: Director

5. Theresa M. Heggie
- Position: Director

6. Anthony J. Doyle
- Position: Director

7. Stephen J. Aselage
- Position: Director

8. Nancy J. Hutson
- Position: Director

9. Amy E. McKee
- Position: Director

10. Steven K. Galson
- Position: Director

11. Vincent J. Milano
- Position: Director ,

Biocryst Pharmaceuticals Inc currently has 435 employees.

News about Biocryst Pharmaceuticals Inc Key Personnel

BioCryst's ORLADEYO Achieves Remarkable Growth, Forecasts Accelerated Path to Profitability

In a significant stride towards medical breakthroughs, renowned pharmaceutical company BioCryst Pharmaceuticals recently announced its preliminary full-year net revenue for 2023, hitting an impressive milestone of $325 million. The remarkable 29 percent year-on-year growth recorded by their flagship product, ORLADEYO (berotralstat), showcases BioCryst s unwavering commitment to revolutionizing the treatment of rare diseases. With this extraordinary achievement, the company also provides a glimpse into its 2024 guidance and an accelerated path to profitability.
ORLADEYO s Stellar Performance:
ORLADEYO, an oral therapy designed to prevent hereditary angioedema (HAE) attacks, has carved out a ...